Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...

Native Instruments' NKS Hardware Partner Program launches today, bringing NKS compatibility to owners of a handful of its ...

Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lemaitre Vascular (LMAT – Research Report), ...

Therapeutics announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics ...

SAN FRANCISCO and NEW YORK - Nektar Therapeutics (NASDAQ: NASDAQ:NKTR), a clinical-stage biotechnology company currently trading at $0.93 per share with a market capitalization of $173 million ...

Management report In 2024 AS Linda Nektar (The Company's) unaudited turnover was EUR 2,543,793 (12 months 2023: EUR 2,489,789). This marked an increase of 2.2% year-on-year and was largely identical ...

Nektar Therapeutics today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...